NovaBridge Biosciences

Healthcare · Biotechnology · United States

Last price 1.195 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 138.62M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab a...